Results 71 to 80 of about 1,192 (126)

Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease. [PDF]

Cell Rep Med
Nieto P, Klinsing S, Caratù G, Dettki M, Marchese D, Weber KJ, Morabito S, Lorden P, Ruano I, Imkeller K, Velasco MA, Vidal S, Melero JL, Euskirchen P, Czabanka M, Plate KH, Harter PN, Pascual-Reguant A, Steinbach JP, Heyn H, Zeiner PS, Nieto JC.   +21 more
europepmc   +1 more source

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma. [PDF]

J Hematol Oncol
Kaulen LD, Karschnia P, Doubrovinskaia S, Abramson JS, Soumerai JD, Martinez-Lage M, Haydu JE, Shankar GM, Patel C, Choi BD, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J.   +18 more
europepmc   +1 more source

Sustainable Bio-Based Plasticizers: Advances in Polyols and Natural Compound Derivatives from Sorbitol, Glycerol, Cardanol, and Limonene. [PDF]

Polymers (Basel)
Ghazzy AM, Shraim AS, Al-Sammarraie TR, Al-Mohammadi WM, Al-Hunaiti AH.   +4 more
europepmc   +1 more source

The many facets of sustainability in medicinal chemistry: our personal experience. [PDF]

RSC Med Chem
Martinengo B, Diamanti E, Uliassi E, Bolognesi ML.   +3 more
europepmc   +1 more source

Relapsed or refractory central nervous system lymphoma successfully treated by glofitamab combined with lenalidomide. [PDF]

Front Oncol
Peng YY, Tang XQ.
europepmc   +1 more source

Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma. [PDF]

Cancer Immunol Immunother
Yu L, Ping N, Zou R, Zhu Q, Li J, Zhang X, Xia F, He J, Tu J, Kong D, Wu D, Jin Z, Qu C.   +12 more
europepmc   +1 more source

Unsaturation-Driven Modulation of Antioxidant and Acetylcholinesterase Inhibitory Activities of Cardanol Derivatives. [PDF]

Bioengineering (Basel)
Rodrigues Valério RB, de Souza H, Martins V, Silva K, de Manezes JE, Chaves A, Serafim LF, Vieira-Neto A, Dos Santos JCS, de Morais S.   +9 more
europepmc   +1 more source

CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier. [PDF]

Front Med (Lausanne)
Li D, Liu R, Fu Z, Yang F, Ma L, Cao M, Guo Y, Deng B, Chang AH, Zheng Q, Ke X, Hu K.   +11 more
europepmc   +1 more source

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma. [PDF]

Blood Adv
Neumann MA, Schneider J, Szameitat M, Schommers P, Borchmann S, Hallek M, Borchmann P, Heger JM.   +7 more
europepmc   +1 more source

Production of Organic Acids from Cashew Nut Shell Liquid (CNSL) via Electrochemical Synthesis. [PDF]

Int J Mol Sci
Ducuara JA, Arrieta AA, Calabokis OP.
europepmc   +1 more source